CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Enzymatica AB (publ) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Enzymatica AB (publ)
Ideon Science Park, Scheelevagen 19
Phone: +46 462863100p:+46 462863100 LUND, 223 70  Sweden Ticker: ENZYENZY

Business Summary
Enzymatica AB (publ) is a Sweden-based life science company that develops and sells medical devices for infection-related diseases. The Company deals with research, development and sales of products based on enzyme technology and related activities. Enzymatica AB (publ) develops solutions that support the body's own defenses against virus, irritants and microorganisms. The Company offers products which are based on a barrier technology, includes marine enzymes. Enzymatica AB (publ) focuses on product development based on the tested and patented barrier technology used in the common cold product ColdZyme, a mouth spray that protects against colds, can help shorten the duration of the cold if used in the early stages of infection, relieves cold symptoms, and soothes sore throats.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
Yes--Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202412/31/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board BengtBaron 62 9/8/2021 12/19/2016
Chief Executive Officer ClausEgstrand 63 1/1/2024 6/1/2017
Deputy Chief Executive Officer, Chief Financial Officer ThereseFilmersson 55 1/1/2022 1/1/2018
8 additional Officers and Directors records available in full report.

Business Names
Business Name
ENZY
Zymetech

General Information
Number of Employees: 21 (As of 12/31/2024)
Outstanding Shares: 242,735,108 (As of 12/31/2024)
Stock Exchange: STO


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 28, 2025